Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronar

[1]  D. Angiolillo,et al.  A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. , 2016, European heart journal.

[2]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[3]  D. Angiolillo,et al.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease , 2016, Nature Reviews Cardiology.

[4]  K. Anstrom,et al.  In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study , 2015, European heart journal. Acute cardiovascular care.

[5]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[6]  K. Anstrom,et al.  Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study , 2015, Circulation. Cardiovascular interventions.

[7]  W. Cantor,et al.  Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. , 2014, The Canadian journal of cardiology.

[8]  J. Siller-Matula,et al.  Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry , 2014, BMJ Open.

[9]  Deepak L. Bhatt,et al.  In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry , 2014, Circulation. Cardiovascular interventions.

[10]  Eric D. Peterson,et al.  Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.

[11]  G. Veress,et al.  Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. , 2014, Journal of the American College of Cardiology.

[12]  P. Damman,et al.  Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). , 2014, The American journal of cardiology.

[13]  D. Sibbing,et al.  A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients , 2013, Thrombosis and Haemostasis.

[14]  K. Huber,et al.  Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention , 2013, European heart journal.

[15]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[16]  C. Stefanadis,et al.  Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). , 2013, International Journal of Cardiology.

[17]  M. Effron,et al.  Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): A Randomized Controlled Trial , 2013, Circulation. Cardiovascular interventions.

[18]  M. Price,et al.  Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. , 2013, International journal of cardiology.

[19]  G. Maurer,et al.  Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. , 2013, International journal of cardiology.

[20]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[21]  C. Coleman,et al.  Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. , 2013, The American journal of cardiology.

[22]  Seung‐Jung Park,et al.  Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. , 2013, American heart journal.

[23]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[24]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[25]  W. Kim,et al.  Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. , 2012, JACC. Cardiovascular interventions.

[26]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[27]  D. Aradi,et al.  Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention , 2012, Journal of Thrombosis and Thrombolysis.

[28]  S. Werns.  Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial , 2012 .

[29]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[30]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[31]  K. Anstrom,et al.  Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. , 2011, American heart journal.

[32]  M. Price,et al.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.

[33]  Betti Giusti,et al.  High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. , 2011, JAMA.

[34]  P. Teirstein,et al.  Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.

[35]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[36]  M. Pansieri,et al.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.

[37]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[38]  K. Alexander,et al.  In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. , 2011, The American journal of cardiology.

[39]  V. Pasceri,et al.  Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). , 2011, The American journal of cardiology.

[40]  T. Costigan,et al.  Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. , 2010, Journal of the American College of Cardiology.

[41]  J. Eikelboom,et al.  Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study , 2010, Circulation.

[42]  A. Kastrati,et al.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement , 2010, Journal of thrombosis and haemostasis : JTH.

[43]  P. Morange,et al.  Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[44]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[45]  Françoise Dignat-George,et al.  Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. , 2009, The American journal of cardiology.

[46]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[47]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[48]  S. Steinhubl,et al.  Platelet function monitoring in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[49]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[50]  F. Neumann,et al.  Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.

[51]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[52]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.